US Pharma MarketingNovartis commits $1.1B upfront to take Myricx Bio and its next-gen ADC platform
Novartis pays $1.1B upfront (up to $1.5B total) for Myricx Bio, gaining its NMT inhibitor ADC payload platform and two preclinical oncology assets. Topic Hubs AI drug discovery: News, analysis and interviews Antibody-drug conjugates: The next wave of targeted cancer drugs Biopharma M&A and dealmaking: Who’s buying and why Biopharma people moves: CEO changes, executive hires, board positions Biotech IPOs: Tracking the market for new public offerings Biotech venture funding: Who’s raising and where the money is going Cell and gene therapy manufacturing: Scaling the next frontier China biotech: Licensing deals and the Biosecure Act CRISPR and gene editing: The…
Novartis said Monday it will be spending $1.1 billion upfront to buy Myricx Bio, which has an ADC payload platform that could offer an edge over current approaches.
The Swiss drugmaker will get Myricx’s NMT ...
Source: Endpoints News